April 2019 pharmaceutical M&A round-up

There were few big acquisitions involving major drugmakers to get pulses racing in April, but that is not to say that it was an unimportant month in pharma M&A.

There were updates in Bristol-Myers Squibb's (NYSE: BMY) attempt to take over Celgene (Nasdaq: CELG) and Roche's (ROG: SIX) deal for Spark Therapeutics (Nasdaq: ONCE), two of the biggest takeovers attempted in the year so far.

There was also a second acquisition of the year to be announced by Czech Republic-based generics drugmaker Zentiva Group, and a deal worth more than $1 billion for a gene therapy manufacturing company.